Response to ‘Serum level of adiponectin is a surrogate independent biomarker of radiographic disease progression in early rheumatoid arthritis: results from the ESPOIR cohort’ – authors’ reply

  • Jérémie Sellam4, 5, 3, 4,

    Affiliated with

    • Soraya Fellahi5, 3, 4, 5,

      Affiliated with

      • Jean-Philippe Bastard5, 3, 4, 5,

        Affiliated with

        • Jacqueline Capeau5, 3, 4, 5 and

          Affiliated with

          • Francis Berenbaum4, 5, 3, 4Email author

            Affiliated with

            Arthritis Research & Therapy201416:408

            DOI: 10.1186/ar4538

            Published: 10 April 2014

            We thank Dr Toussirot for his interest [1] in our work demonstrating that serum-level adiponectin is associated with subsequent radiographic progression in early rheumatoid arthritis (RA) [2]. We would like to respond to each comment.

            First, our objective was not to determine whether the serum adipokine level might reflect RA disease activity cross-sectionally, but was to find surrogate markers able to predict structural radiographic progression. We performed such an analysis and found no correlation between any serum adipokine levels and the disease activity score in 28 joints (data not shown).

            Concerning the second and third points, the association we found between the total adiponectin concentration and radiographic progression does not provide any direct indications about any functional roles of this adipokine in RA. Despite an anti-inflammatory role of adiponectin, adiponectin isoforms are proinflammatory on RA synovial cells, in accordance with our results [3]. Moreover, although adiponectin may be protective in collagen-induced arthritis, its proinflammatory effect is well known in other inflammation models [4].

            Concerning the fourth point about potential discrepancies between a recently published cross-sectional study [5] and our own work, the comparison is challenging since we have not assessed the high molecular weight (HMW) isoform and have not investigated healthy control subjects. Moreover, Toussirot and colleagues did not study the structural progression. Finally, they investigated treated patients with established RA, while we focused on untreated patients with early RA. Furthermore, the use of an enzyme-linked immunosorbent assay for HMW assessment and a radioimmunoassay for total adiponectin assessment may explain the absence of correlation between both measurements. Recently, a high correlation between both isoforms using enzyme-linked immunosorbent assay for both measurements has been reported in RA [6].

            Finally, we fully agree on discrepancies between published studies investigating the serum adiponectin level in RA as noted in the fifth point by Toussirot [1]. Although this can be due to the need to assess HMW rather than total adiponectin, the high correlation using an enzyme-linked immunosorbent assay does not support such a hypothesis. The demographic characteristics, the adjustment for confounding factors, and the sample size of the population may explain these divergences. Of note, our study involved the largest group of early RA adipokine measurements to date with multiple adjustments.

            In conclusion, while our study has emphasized the usefulness of serum total adiponectin measurement as an accurate biomarker predicting radiographic progression, additional studies are necessary to establish whether the serum HMW adiponectin measurement may be more useful for such a purpose.

            Abbreviations

            HMW: 

            High molecular weight

            RA: 

            Rheumatoid arthritis.

            Declarations

            Authors’ Affiliations

            (1)
            Service de Rhumatologie, Hôpital Saint-Antoine
            (2)
            Inflammation–Immunopathology–Biotherapy i2B Department
            (3)
            UPMC Université Paris 06
            (4)
            INSERM, UMR_S 938, Faculté de Médecine
            (5)
            Department of Biochemistry, AP-HP, Hopital Tenon

            References

            1. Toussirot E: Response to ‘Serum level of adiponectin is a surrogate independent biomarker of radiographic disease progression in early rheumatoid arthritis: results from the ESPOIR cohort’. Arthritis Res Ther 2014, 16:407.View Article
            2. Meyer M, Sellam J, Fellahi S, Kotti S, Bastard JP, Meyer O, Lioté F, Simon T, Capeau J, Berenbaum F: Serum level of adiponectin is a surrogate independent biomarker of radiographic disease progression in early rheumatoid arthritis: results from the ESPOIR cohort. Arthritis Res Ther 2013, 15:R210.PubMed CentralPubMedView Article
            3. Frommer KW, Schäffler A, Büchler C, Steinmeyer J, Rickert M, Rehart S, Brentano F, Gay S, Müller-Ladner U, Neumann E: Adiponectin isoforms: a potential therapeutic target in rheumatoid arthritis? Ann Rheum Dis 2012, 71:1724–1732.PubMedView Article
            4. Miller M, Pham A, Cho JY, Rosenthal P, Broide DH: Adiponectin-deficient mice are protected against tobacco-induced inflammation and increased emphysema. Am J Physiol Lung Cell Mol Physiol 2010, 299:L834-L842.PubMed CentralPubMedView Article
            5. Toussirot E, Grandclément E, Gaugler B, Michel F, Wendling D, Saas P, Dumoulin G: CBT-506: Serum adipokines and adipose tissue distribution in rheumatoid arthritis and ankylosing spondylitis, A comparative study. Front Immunol 2013, 4:453.PubMed CentralPubMedView Article
            6. Dessein PH, Woodiwiss AJ, Norton GR, Tsang L, Solomon A: Independent associations of total and high molecular weight adiponectin with cardiometabolic risk and surrogate markers of enhanced early atherogenesis in black and white patients with rheumatoid arthritis: a cross-sectional study. Arthritis Res Ther 2013, 15:R128.PubMed CentralPubMedView Article

            Copyright

            © The Author(s) 2014

            This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

            Advertisement